CG Oncology Inc. Common s... (CGON)
NASDAQ: CGON
· Real-Time Price · USD
33.34
0.18 (0.54%)
At close: Sep 12, 2025, 3:59 PM
33.34
0.00%
After-hours: Sep 12, 2025, 04:57 PM EDT
0.54% (1D)
| Bid | 33.28 |
| Market Cap | 2.54B |
| Revenue (ttm) | 551K |
| Net Income (ttm) | -86.66M |
| EPS (ttm) | -1.78 |
| PE Ratio (ttm) | -18.73 |
| Forward PE | -15.01 |
| Analyst | Buy |
| Ask | 33.43 |
| Volume | 1,356,578 |
| Avg. Volume (20D) | 882,780 |
| Open | 32.98 |
| Previous Close | 33.16 |
| Day's Range | 32.57 - 34.46 |
| 52-Week Range | 14.80 - 40.47 |
| Beta | 0.88 |
About CGON
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CGON
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CGON stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
CG Oncology Inc. Common stock is scheduled to release its earnings on
Nov 11, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+6.88%
CG Oncology shares are trading higher after the co...
Unlock content with
Pro Subscription
4 months ago
+4.72%
CG Oncology shares are trading higher after JP Morgan initiated coverage on the stock with an Overweight rating and announced a price target of $41.
1 month ago · fool.com
Cg Oncology (CGON) Q2 Loss Widens 93%Cg Oncology (CGON) Q2 Loss Widens 93%
2 months ago · seekingalpha.com
CG Oncology: Looking Undervalued Heading Toward FDA Submission (Upgrade)CG Oncology, Inc.'s cretostimogene shows strong efficacy and safety in late-stage bladder cancer trials, with promising complete response rates and durable activity. The company boasts a robust cash p...